Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at UBS Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a $978.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $660.00. UBS Group’s target price points to a potential upside of 22.81% from the company’s current price.

A number of other research analysts have also recently issued reports on REGN. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Robert W. Baird boosted their price target on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Evercore increased their price objective on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, The Goldman Sachs Group raised their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $845.21.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $17.98 during trading on Thursday, hitting $796.34. 798,824 shares of the stock traded hands, compared to its average volume of 822,409. The stock has a market cap of $81.99 billion, a price-to-earnings ratio of 19.68, a P/E/G ratio of 1.30 and a beta of 0.16. Regeneron Pharmaceuticals has a one year low of $564.00 and a one year high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $791.11 and a 200 day simple moving average of $720.89.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.81 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals will post 47.93 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 8,093 shares of company stock worth $6,506,845. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. Purus Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $235,000. Mainsail Asset Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $234,000. B.A. Schrock Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $1,608,000. Mather Group LLC. raised its position in shares of Regeneron Pharmaceuticals by 10.0% during the third quarter. Mather Group LLC. now owns 870 shares of the biopharmaceutical company’s stock worth $660,000 after purchasing an additional 79 shares during the period. Finally, Fortitude Family Office LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 67.9% during the 3rd quarter. Fortitude Family Office LLC now owns 47 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 19 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS initiated a “Buy” rating on Regeneron, arguing that Wall Street is undervaluing the long-term growth potential of Dupixent, the company’s key immunology drug marketed with Sanofi. Regeneron a new buy at UBS as Street undervalues Dupixent’s future
• Positive Sentiment: Regeneron has reportedly finished paying down its balance owed to Sanofi. That should allow the company to retain more of the economics from the partnership and could improve reported revenue and profitability going forward. What Could Send Regeneron Stock Higher?
• Positive Sentiment: Analysts are anticipating double-digit bottom-line growth when Regeneron reports third-quarter results later this month, creating a near-term catalyst if earnings and guidance exceed expectations. What to Expect From Regeneron Pharmaceuticals’ Next Quarterly Earnings Report
• Neutral Sentiment: A review of second-quarter biotechnology results included Regeneron among industry performers, but the available report summary does not identify a new company-specific catalyst. Q2 Earnings Highlights: Regeneron Vs The Rest Of The Biotechnology Stocks
• Negative Sentiment: Executive Andrew Murphy sold 4,147 Regeneron shares worth approximately $3.2 million, reducing his direct holdings by 7.98%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a bearish signal. SEC insider transaction filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.